Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
Trial record 26 of 96297 for:    5

Use of Dapsone Gel, 5% for Treating Dermatitis Herpetiformis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01115244
Recruitment Status : Terminated (poor enrollment and lack of funding)
First Posted : May 4, 2010
Results First Posted : December 14, 2017
Last Update Posted : December 14, 2017
Sponsor:
Information provided by (Responsible Party):
Vanderbilt University Medical Center

Tracking Information
First Submitted Date  ICMJE April 23, 2010
First Posted Date  ICMJE May 4, 2010
Results First Submitted Date  ICMJE November 15, 2017
Results First Posted Date  ICMJE December 14, 2017
Last Update Posted Date December 14, 2017
Actual Study Start Date  ICMJE July 2010
Actual Primary Completion Date March 2012   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 29, 2010)
Number and Size of All Lesions on the Treated and Untreated Elbows or Knees of Patients With Dermatitis Herpetiformis Who Have One Extremity Treated With Dapsone Gel, 5% [ Time Frame: 6 weeks of treatment ]
The primary objective is to evaluate the efficacy of dapsone gel, 5% in the treatment of dermatitis herpetiformis. The primary efficacy end point will be the proportion of patients achieving success based on mean % reduction from baseline in total lesion counts at week six. Digital photographs of each elbow or each knee (treatment and control) will be taken. The number and size of lesions will be recorded for the treatment and control elbow or knee. This process will be repeated at each follow up visit.
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT01115244 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: April 29, 2010)
  • Number of Papules, Plaques and Vesicles on Treated and Untreated Elbows or Knees of Patients Who Have One Extremity Treated With Dapsone Gel, 5% [ Time Frame: 6 weeks of treatment ]
    Lesion types will be counted at recorded at each visit. The mean lesion counts for papules, plaques and vesicles, as well as mean reduction of disease burden from baseline at week six for each of these categories, will be determined.
  • Evaluation of Clinical Photographs and Scoring of Photographs Based on a Modified Global Acne Assessment Score [ Time Frame: 6 weeks of treatment ]
    Photographs of the treated and control extremity of each patient will be presented to the investigator in a blinded manner. Scores will be assigned according to a modified Global Acne Assessment Score. This scoring system has previously been used to evaluate the efficacy of dapsone gel, 5% in the treatment of acne. The designated score is based on disease severity, number of lesions, and type of lesions.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Use of Dapsone Gel, 5% for Treating Dermatitis Herpetiformis
Official Title  ICMJE Dapsone Gel, 5% for Topical Treatment of Dermatitis Herpetiformis
Brief Summary The primary objective of this study is to evaluate the efficacy of dapsone gel, 5% in the treatment of dermatitis herpetiformis. The primary efficacy end point will be the proportion of patients achieving success based on mean % reduction from baseline in total lesion counts at week six. Success for lesion reduction will be defined as statistically greater mean percent reductions at week six in the dapsone gel-treated extremity compared with the control extremity of each patient.
Detailed Description

The study will be a prospective evaluation of dapsone gel, 5% in patients with a clinical diagnosis of dermatitis herpetiformis. Active disease must occur on the patients' bilateral elbows or bilateral knees at the time of study enrollment. Active disease will be defined as five or more papules/pustules/vesicles on an extremity. Randomization of one of the patient's extremities (either one elbow or one knee) to the treatment group will occur at time of enrollment. Randomization will be in the sequence of right side assigned to odd numbered patients and left side assigned to even numbered patients. Thus, the first patient to be enrolled, patient number one, would be randomized to treatment on his or her right side. Depending on the site of active disease, he or she would apply topical dapsone gel, 5% to the right elbow or knee twice daily for the duration of the study.

No blinding of the patients or the PI will occur. The co-investigator will be blinded to whether the photographs presented to him at the end of the study are those of a treated or untreated extremity.

The patients will be screened for study enrollment in a private clinic room within the dermatology clinic at One Hundred Oaks. Patients will be presented with a study summary sheet and a consent form. They will be allowed to ask questions pertaining to the study protocol. Information provided to them will be that found in the study protocol alone. If desired, informed consent can be taken home with the patient to consider, and enrollment can be performed at a later date. In that instance, the patient would be brought back for an additional visit at the time of consent and study enrollment. Study enrollment and first treatment will be performed on the day of study consent. Digital photographs of each elbow or each knee (treatment and control) will be taken on the day of enrollment to serve as a baseline evaluation. The number of lesions (including papules, plaques and vesicles) will be recorded for the treatment and control elbow or knee. Measurements of each lesion will be taken and recorded as well. This data will be written in a chart and stored in the PI's notebook in a locked cabinet in the department of dermatology. Digital photographs will be printed out on the same day as the visit and placed in the notebook as well. Two copies of each photograph will be made. Each photograph will be assigned a letter, A through Z, based on a code for each patient. One copy of each set of photographs will also include the date. No patient identifiable features will be included in the photograph such as the face or eyes. Each photograph will be of the treated or control area only. The code to identify patient photographs will be assigned by the Data and Safety Monitor and kept in a separate locked cabinet. The code will be broken following the blinded evaluation of the photographs by co-investigator.

The patient will be given oral instructions regarding the application of topical dapsone gel, 5% by the PI on the day of enrollment. The PI will apply the first treatment to the randomized extremity during the first clinic visit. The patient will then remain in the treatment room for fifteen minutes to evaluate for any immediate adverse reaction. The PI will remain in the room with the patient. At the end of the fifteen minute evaluation, the patient will be sent home with written instructions for application and a 30gm tube of ACZONE™ (dapsone) Gel, 5%. Patients will apply the study drug to the indicated elbow or knee each morning and evening for the two weeks. They will return to the dermatology clinic in two weeks and be seen in a private clinic room by the PI for a follow up visit. At that time, photographs, lesion counts and measurements will be taken again, just as they were at the initial visit. The patient will be asked to report any adverse events at that time. Patients will be instructed to continue treatment and follow up in two weeks. The same parameters will be evaluated at the four week visit and again at the six week visit, which will be the completion of the study.

Patients will discontinue treatment after six weeks. The co-investigator will be presented will all photograph marked with the patient letter only. He will not know the sequence of the photographs or dates taken. He will then assign a number according to his subjective evaluation of the clinical photographs, while also being blinded to which elbow or knee was treated, right or left. The scores assigned will follow the criteria listed in the investigator's Dermatitis Herpetiformis Assessment Score. The code to the photographs will be broken after the completion of photograph evaluation. Photographs of a set will be matched to those with both letter and date to determine the scores in chronological order.

Six weeks after completion of treatment each patient will be contacted by phone and asked a series of five questions. That will conclude the study.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Dermatitis Herpetiformis
Intervention  ICMJE Drug: Dapsone gel, 5%
ACZONE™ (dapsone) Gel, 5% will be applied to one elbow or knee, randomized at time of enrollment. Application will be topical to the same location twice daily (morning and evening) for six weeks.
Other Name: ACZONE™ (dapsone) Gel, 5%
Study Arms  ICMJE
  • Experimental: Dapsone gel, 5%
    ACZONE™ (dapsone) Gel, 5% will be applied to one elbow or knee, randomized at time of enrollment. Application will be topical to the same location twice daily (morning and evening) for six weeks.
    Intervention: Drug: Dapsone gel, 5%
  • No Intervention: Not treated
    One arm of the patient will be left untreated.
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: November 15, 2017)
1
Original Estimated Enrollment  ICMJE
 (submitted: April 29, 2010)
5
Actual Study Completion Date  ICMJE March 2012
Actual Primary Completion Date March 2012   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Age 12 years or older
  • Clinical diagnosis of dermatitis herpetiformis, as previously diagnosed by the patient's primary dermatologist or diagnosed by agreement of the two investigators
  • Active disease at time of enrollment, defined as at least five inflammatory lesions (to include papules, plaques and vesicles) on the bilateral elbows or bilateral knees

Exclusion Criteria:

  • Patients taking oral dapsone or those who have taken oral dapsone within four weeks prior to enrollment
  • Patients using any other topical treatment for dermatitis herpetiformis at time of enrollment or within the four weeks prior to enrollment
  • Patients with known allergy or hypersensitivity to dapsone, sulfa drugs or excipients of the dapsone gel product
  • Women will be excluded if pregnant or nursing
  • Women of childbearing potential must be practicing an effective method of birth control as determined by the enrolling physician. If oral contraceptives are the method of choice, then the patient must have been on a stable dose for a minimum of 3 months. (This is the same guideline used for women of childbearing potential in previous studies of acne patients.)
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 12 Years and older   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01115244
Other Study ID Numbers  ICMJE 100273
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Vanderbilt University Medical Center
Study Sponsor  ICMJE Vanderbilt University Medical Center
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Vanderbilt University Medical Center
Verification Date November 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP